Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2602 | Non-convalescent Plasma (control plasma) Wiki | 0.71 |
| drug2587 | No interverntion Wiki | 0.71 |
| drug1031 | Control (albumin 5%) Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009202 | Cardiomyopathies NIH | 0.41 |
| D002318 | Cardiovascular Diseases NIH | 0.25 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001638 | Cardiomyopathy HPO | 0.41 |
| HP:0001626 | Abnormality of the cardiovascular system HPO | 0.24 |
Navigate: Correlations HPO
There are 2 clinical trials
This randomized blinded multi-center phase 2 trial will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma among adults with severe COVID-19. Adults ≥18 years of age may participate. A total of 219 eligible subjects will be randomized in a 2:1 ratio to receive either high-titer anti-SARS-CoV-2 plasma or non-convalescent fresh frozen plasma (control plasma).
Description: Compare the day 28 severity outcome amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups using a 7-point ordinal scale of clinical status.
Measure: Day 28 severity outcome Time: Up to 28 daysDescription: Compare the proportion and duration of SARS-CoV-2 PCR positivity (via RT-PCR) amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups at days 0, 7, and 14.
Measure: Proportion of SARS-CoV-2 PCR Positivity Time: Up to 14 daysDescription: Compare levels of SARS-CoV-2 RNA amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups at days 0, 7, and 14.
Measure: Levels of SARS-CoV-2 RNA Time: Up to 14 daysDescription: Compare duration of need for supplemental oxygen and/or mechanical ventilation amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.
Measure: Duration of Need for Supplemental Oxygen Time: Up to 28 daysDescription: Compare duration of hospitalization amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.
Measure: Duration of Hospitalization Time: Up to 28 daysDescription: Compare in-hospital and 28-day mortality amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.
Measure: In-hospital and 28-day mortality Time: Up to 28 daysDescription: Compare time-to-clinical improvement in-hospital amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups, defined as the time to either an improvement of one point on a 7-point ordinal scale of clinical status or alive discharge from the hospital, whichever comes first.
Measure: Time-to-clinical improvement in-hospital Time: Up to 28 daysDescription: To assess for host genetic differences at Day 0 amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.
Measure: Host genetic differences at day 0 Time: Day 0Description: To assess for host transcriptomic differences at Day 0,7,14 amongst the anti-SARS-CoV-2 convalescent plasma and non-convalescent plasma groups.
Measure: Host transcriptomic differences at days 0,7,14 Time: Up to 14 daysThis is a double-blinded, randomized control trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in two groups, RT PCR-positive and asymptomatic or mildly symptomatic at baseline (group B) and PCR-negative at baseline (group C). Both groups will be randomized 1:1 to receive either convalescent plasma qualitatively positive for SARS-CoV-2 antibody (anti-SARS-CoV-2 plasma) or control (albumin 5%).
Description: The efficacy of treatment will be determined by rating disease severity on Day 28, or last rating evaluated, using a seven-category severity scale.
Measure: Rate of Severe Disease Time: Up to 28 daysDescription: To compare the rate of measurable anti-SARS-CoV-2 titers between recipients of CP (anti-SARS-CoV-2 plasma) versus control (albumin 5%).
Measure: Rate of measurable anti-SARS-CoV-2 titers Time: Up to 90 daysDescription: Compare the rates of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (albumin 5%).
Measure: Rate of SARS-CoV-2 PCR Positivity Time: Up to 28 daysDescription: Compare the duration of SARS-CoV-2 PCR positivity (RT PCR) amongst the anti-SARS-CoV-2 convalescent plasma and control (albumin 5%).
Measure: Duration of SARS-CoV-2 PCR Positivity Time: Up to 28 daysDescription: Compare the levels of SARS-CoV-2 RNA between the recipients of antiSARS-CoV-2 plasma and control (albumin 5%)
Measure: Levels of SARS-CoV-2 RNA Time: Up to 28 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports